<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092923</url>
  </required_header>
  <id_info>
    <org_study_id>03749</org_study_id>
    <nct_id>NCT01092923</nct_id>
  </id_info>
  <brief_title>Physiological Effects of Nitrous Oxide on Anaesthesia</brief_title>
  <official_title>Nitrous Oxide and Inhalational Agent Pharmacokinetics During Anaesthetic Induction and Emergence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austin Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Austin Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nitrous oxide is the oldest anaesthetic agent still in routine use today. Despite huge
      changes in the pharmacology of volatile anaesthetic agents and intravenous anaesthetics, the
      unique properties of nitrous oxide have maintained its place in modern practice, where it is
      used in combination with other, more powerful inhaled agents, such as sevoflurane. It has
      useful analgesic properties, unlike the other agents used today, and its inclusion reduces
      the concentration of other agents required to maintain an adequate depth of anaesthesia for
      surgery.

      In particular, its low solubility in body tissues gives it a unique pharmacokinetic profile,
      with rapid washin and washout from the body. It has been shown to have a similar effect on
      the speed of uptake of accompanying agents like sevoflurane (the &quot;second gas effect&quot;), which
      have much slower pharmacokinetics. A recent study by us suggested that this promotes faster
      and smoother onset of anaesthesia, as measured using the standard monitor of depth of
      anaesthesia (the BIS monitor). This finding requires confirmation prospectively in a larger
      group of patients. The investigators further hypothesise that a similar effect also exists on
      washout of sevoflurane at the end of the procedure, promoting quicker recovery (emergence)
      from anaesthesia. This has never been previously demonstrated. This information will help
      better define the place of nitrous oxide in achieving optimal outcomes in modern anaesthetic
      practice. The investigators propose to conduct a simple study to measure the effects of
      nitrous oxide washin and washout on exhaled concentrations of accompanying sevoflurane during
      both induction of anaesthesia and emergence, and identify any accompanying effect on the rate
      of change in depth of anaesthesia using BIS. The investigators hypothesise that the rate of
      fall of exhaled sevoflurane concentration at the end of anaesthesia will be more rapid in the
      group of patients breathing a gas mixture containing nitrous oxide, and that the rate of fall
      of BIS on induction and the rate of rise of BIS on emergence will be faster in the nitrous
      oxide group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nitrous oxide is the oldest anaesthetic agent still in routine use today. Despite huge
      changes in the pharmacology of volatile anaesthetic agents and intravenous anaesthetics, the
      unique properties of nitrous oxide have maintained its place in modern practice, where it is
      used in combination with other, more powerful inhaled agents, such as sevoflurane. It has
      useful analgesic properties, unlike the other agents used today, and its inclusion reduces
      the concentration of other agents required to maintain an adequate depth of anaesthesia for
      surgery. In particular, its low solubility in body tissues gives it a unique pharmacokinetic
      profile, with rapid washin and washout from the body. It has been shown to have a similar
      effect on the speed of uptake of accompanying agents like sevoflurane (the &quot;second gas
      effect&quot;), which have much slower pharmacokinetics.

      A recent study by us suggested that this promotes faster and smoother onset of anaesthesia,
      as measured using the standard monitor of depth of anaesthesia (the BIS monitor). This
      finding requires confirmation prospectively in a larger group of patients.

      We further hypothesise that a similar effect also exists on washout of sevoflurane at the end
      of the procedure, promoting quicker recovery (emergence) from anaesthesia. This has never
      been previously demonstrated. This information will help better define the place of nitrous
      oxide in achieving optimal outcomes in modern anaesthetic practice.

      We propose to conduct a simple study to measure the effects of nitrous oxide washin and
      washout on exhaled concentrations of accompanying sevoflurane during both induction of
      anaesthesia and emergence, and identify any accompanying effect on the rate of change in
      depth of anaesthesia using BIS.

      Consenting adult participants will be recruited who are undergoing general anaesthesia for
      elective surgery anticipated to take a minimum of 1 hour and where an arterial line is
      considered appropriate for monitoring of blood pressure.

      As, in normal practice, the decision whether to include of nitrous oxide in the anaesthetic
      mixture is largely discretionary on the part of the anaesthetist, and therefore allocation to
      either arm of the protocol is consistent with routine practice, it is intended that the
      patients will be approached for consent on admission to hospital for their surgery. Standard
      patient monitoring will be used including BIS and a 2 mL sample of blood will be taken to
      assess blood gas content lung function and optimise lung ventilation.

      Following induction of anaesthesia, participants will receive an inhaled gas mixture
      containing standard concentrations of sevoflurane. They will be randomised to a treatment
      group where a standard concentration of nitrous oxide is included in this mixture, or a
      control group where nitrous oxide is not included. Monitoring and recording of exhaled gas
      concentrations will be made by continuous sampling of gas from the breathing circuit and
      computer storage. We hypothesise that the rate of fall of exhaled sevoflurane concentration
      at the end of anaesthesia will be more rapid in the group of patients breathing a gas mixture
      containing nitrous oxide, and that the rate of fall of BIS on induction and the rate of rise
      of BIS on emergence will be faster in the nitrous oxide group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pa t/Pa0 Sevo (Arterial Partial Pressure of Sevoflurane), t=Time(Minutes)</measure>
    <time_frame>Baseline, 2 minutes, 5 minutes, and 30 minutes after emergence</time_frame>
    <description>Rate of fall in the arterial partial pressure of sevoflurane relative to baseline at 2 minutes (Pa 2/Pa0 Sevo), 5 minutes (Pa 5/Pa0 Sevo, and 30 minutes (Pa 30/Pa0 Sevo)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PA t/PA0 Sevo (End Tidal Partial Pressure of Sevoflurane), t=Time (Minutes)</measure>
    <time_frame>Baseline, 2 minutes, and 5 minutes after emergence</time_frame>
    <description>Rate of fall in the end-tidal partial pressure of sevoflurane relative to baseline at 2 minutes (PA2/PA0 sevo) and 5 minutes (PA5/PA0 sevo)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Eye Opening</measure>
    <time_frame>20 Minutes</time_frame>
    <description>The time to eye opening to command after cessation of inhalational anaesthetic administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Air/Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevoflurane with Air/Oxygen Mix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sevoflurane in N2O/O2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevoflurane on air/O2</intervention_name>
    <description>sevoflurane on air/O2</description>
    <arm_group_label>Air/Oxygen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevoflurane in N2O/O2</intervention_name>
    <description>sevoflurane in N2O/O2</description>
    <arm_group_label>sevoflurane in N2O/O2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients undergoing elective general or orthopaedic surgery under relaxant
             general anaesthesia anticipated to take &gt;1 hour

        Exclusion Criteria:

          -  Age under 18 years

          -  Morbid obesity BMI &gt; 35

          -  Severe or moderately severe lung disease (FEV1 &lt; 1.0L, FEV1/FVC &lt; 50%)

          -  Past history of severe post-operative nausea and vomiting

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phil Peyton, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austin Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2010</study_first_submitted>
  <study_first_submitted_qc>March 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <results_first_submitted>February 16, 2012</results_first_submitted>
  <results_first_submitted_qc>September 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2012</results_first_posted>
  <last_update_submitted>September 11, 2012</last_update_submitted>
  <last_update_submitted_qc>September 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Austin Health</investigator_affiliation>
    <investigator_full_name>Dr Philip Peyton</investigator_full_name>
    <investigator_title>Staff Anaesthetist</investigator_title>
  </responsible_party>
  <keyword>Nitrous Oxide</keyword>
  <keyword>washin</keyword>
  <keyword>washout</keyword>
  <keyword>second gas effect</keyword>
  <keyword>sevoflurane</keyword>
  <keyword>induction</keyword>
  <keyword>emergence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Nitrous Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of recruitment: December 2009 to April 2010 Location: Austin Health</recruitment_details>
      <pre_assignment_details>Exclusion criteria: patients with history of severe lung disease (defined as FEV1&lt;1.5 L or FEV1/FVC&lt;50%), symptomatic ischemic heart disease, super obesity (BMI&gt;45), pregnancy, prior severe post-operative nausea/vomiting, critically ill/immunocompromised, Vitamin B12/folate deficiency, or presence of any gas-filled, space-occupying lesion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Air/Oxygen</title>
          <description>Sevoflurane with Air/Oxygen Mix</description>
        </group>
        <group group_id="P2">
          <title>Sevoflurane in N2O/O2</title>
          <description>Sevoflurane in 2:1 N2O/O2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Air/Oxygen</title>
          <description>Sevoflurane with Air/Oxygen Mix</description>
        </group>
        <group group_id="B2">
          <title>Sevoflurane in N2O/O2</title>
          <description>Sevoflurane in 2:1 N2O/O2</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="18"/>
                    <measurement group_id="B2" value="67" spread="13"/>
                    <measurement group_id="B3" value="66" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pa t/Pa0 Sevo (Arterial Partial Pressure of Sevoflurane), t=Time(Minutes)</title>
        <description>Rate of fall in the arterial partial pressure of sevoflurane relative to baseline at 2 minutes (Pa 2/Pa0 Sevo), 5 minutes (Pa 5/Pa0 Sevo, and 30 minutes (Pa 30/Pa0 Sevo)</description>
        <time_frame>Baseline, 2 minutes, 5 minutes, and 30 minutes after emergence</time_frame>
        <population>based on data collected during previous pilot study investigating the magnitude of the second gas effect on sevoflurane partial pressures after anaesthesia induction, we expected an effect of roughly similar magnitude would be present during elimination of nitrous oxide.</population>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane in N2O/O2</title>
            <description>N20 with Oxygen (2:1) and Sevoflurane</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane in Air/O2</title>
            <description>Air/Oxygen and Sevoflurane</description>
          </group>
        </group_list>
        <measure>
          <title>Pa t/Pa0 Sevo (Arterial Partial Pressure of Sevoflurane), t=Time(Minutes)</title>
          <description>Rate of fall in the arterial partial pressure of sevoflurane relative to baseline at 2 minutes (Pa 2/Pa0 Sevo), 5 minutes (Pa 5/Pa0 Sevo, and 30 minutes (Pa 30/Pa0 Sevo)</description>
          <population>based on data collected during previous pilot study investigating the magnitude of the second gas effect on sevoflurane partial pressures after anaesthesia induction, we expected an effect of roughly similar magnitude would be present during elimination of nitrous oxide.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 2 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.08"/>
                    <measurement group_id="O2" value="0.44" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 5 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.07"/>
                    <measurement group_id="O2" value="0.32" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.08"/>
                    <measurement group_id="O2" value="0.20" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Eye Opening</title>
        <description>The time to eye opening to command after cessation of inhalational anaesthetic administration</description>
        <time_frame>20 Minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane in N2O/O2</title>
            <description>N20 with Oxygen (2:1) and Sevoflurane</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane in Air/O2</title>
            <description>Air/Oxygen and Sevoflurane</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Eye Opening</title>
          <description>The time to eye opening to command after cessation of inhalational anaesthetic administration</description>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="1.3"/>
                    <measurement group_id="O2" value="11.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PA t/PA0 Sevo (End Tidal Partial Pressure of Sevoflurane), t=Time (Minutes)</title>
        <description>Rate of fall in the end-tidal partial pressure of sevoflurane relative to baseline at 2 minutes (PA2/PA0 sevo) and 5 minutes (PA5/PA0 sevo)</description>
        <time_frame>Baseline, 2 minutes, and 5 minutes after emergence</time_frame>
        <population>based on data collected during previous pilot study investigating the magnitude of the second gas effect on sevoflurane partial pressures after anaesthesia induction, we expected an effect of roughly similar magnitude would be present during elimination of nitrous oxide.</population>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane in N2O/O2</title>
            <description>sevoflurane with N20 and Oxygen in 2:1 mix</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane in Air/O2</title>
            <description>sevoflurane in air/O2 mix</description>
          </group>
        </group_list>
        <measure>
          <title>PA t/PA0 Sevo (End Tidal Partial Pressure of Sevoflurane), t=Time (Minutes)</title>
          <description>Rate of fall in the end-tidal partial pressure of sevoflurane relative to baseline at 2 minutes (PA2/PA0 sevo) and 5 minutes (PA5/PA0 sevo)</description>
          <population>based on data collected during previous pilot study investigating the magnitude of the second gas effect on sevoflurane partial pressures after anaesthesia induction, we expected an effect of roughly similar magnitude would be present during elimination of nitrous oxide.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 2 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.04"/>
                    <measurement group_id="O2" value="0.22" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 5 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.02"/>
                    <measurement group_id="O2" value="0.17" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and/or other [non-serious] adverse events were not collected/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>N20 With Oxygen (2:1)</title>
          <description>sevoflurane with N20 and Oxygen in 2:1 mix</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Phil Peyton</name_or_title>
      <organization>Austin Health</organization>
      <phone>9496 5000 ext 5704</phone>
      <email>phil.peyton@austinhealth.org.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

